Glucagon-like peptide-1 receptor agonists, known as GLP-1 drugs, are highly effective at helping people lose weight and substantially lower the risk of heart attacks, strokes, and death from heart disease. A new study conducted in mice suggests that the drugs’ effect on how blood vessels respond to insulin may be a key driver of this cardiovascular benefit in those with obesity.
This article was originally published on MedicalXpress.com

